全文获取类型
收费全文 | 96991篇 |
免费 | 6676篇 |
国内免费 | 2446篇 |
学科分类
医药卫生 | 106113篇 |
出版年
2023年 | 1472篇 |
2022年 | 2327篇 |
2021年 | 3905篇 |
2020年 | 3683篇 |
2019年 | 3545篇 |
2018年 | 3311篇 |
2017年 | 3150篇 |
2016年 | 3133篇 |
2015年 | 2855篇 |
2014年 | 6319篇 |
2013年 | 6038篇 |
2012年 | 5761篇 |
2011年 | 6723篇 |
2010年 | 5696篇 |
2009年 | 4573篇 |
2008年 | 4325篇 |
2007年 | 4642篇 |
2006年 | 4071篇 |
2005年 | 3520篇 |
2004年 | 2911篇 |
2003年 | 2587篇 |
2002年 | 2016篇 |
2001年 | 1770篇 |
2000年 | 1502篇 |
1999年 | 1394篇 |
1998年 | 1113篇 |
1997年 | 1097篇 |
1996年 | 916篇 |
1995年 | 943篇 |
1994年 | 906篇 |
1993年 | 685篇 |
1992年 | 704篇 |
1991年 | 637篇 |
1990年 | 538篇 |
1989年 | 528篇 |
1988年 | 493篇 |
1987年 | 404篇 |
1986年 | 382篇 |
1985年 | 656篇 |
1984年 | 613篇 |
1983年 | 457篇 |
1982年 | 536篇 |
1981年 | 508篇 |
1980年 | 477篇 |
1979年 | 428篇 |
1978年 | 366篇 |
1977年 | 331篇 |
1976年 | 266篇 |
1975年 | 197篇 |
1974年 | 164篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
熊磊教授以理脾为本,将治痰贯穿始终。根据小儿脾常不足、肾常虚、肝常有余的生理特点,癫痫发作期治疗主以涤痰开窍,辅以理气健脾,同时配合活血化瘀通窍与平肝息风潜阳。主要选方为柴芍温胆汤、天麻钩藤饮、桃红四物汤加减;缓解期则以补肾养肝为主,兼以健脾化痰,主要选方为杞菊地黄丸合定痫丸加减,取得较好临床疗效。 相似文献
3.
4.
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
8.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):94-103.e24
ObjectiveNew-onset postoperative atrial fibrillation (POAF) after cardiac surgery is common, with rates up to 60%. POAF has been associated with early and late stroke, but its association with other cardiovascular outcomes is less known. The objective was to perform a meta-analysis of the studies reporting the association of POAF with perioperative and long-term outcomes in patients with cardiac surgery.MethodsWe performed a systematic review and a meta-analysis of studies that presented outcomes for cardiac surgery on the basis of the presence or absence of POAF. MEDLINE, EMBASE, and the Cochrane Library were assessed; 57 studies (246,340 patients) were selected. Perioperative mortality was the primary outcome. Inverse variance method and random model were performed. Leave-one-out analysis, subgroup analyses, and metaregression were conducted.ResultsPOAF was associated with perioperative mortality (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.58-2.33), perioperative stroke (OR, 2.17; 95% CI, 1.90-2.49), perioperative myocardial infarction (OR, 1.28; 95% CI, 1.06-1.54), perioperative acute renal failure (OR, 2.74; 95% CI, 2.42-3.11), hospital (standardized mean difference, 0.80; 95% CI, 0.53-1.07) and intensive care unit stay (standardized mean difference, 0.55; 95% CI, 0.24-0.86), long-term mortality (incidence rate ratio [IRR], 1.54; 95% CI, 1.40-1.69), long-term stroke (IRR, 1.33; 95% CI, 1.21-1.46), and longstanding persistent atrial fibrillation (IRR, 4.73; 95% CI, 3.36-6.66).ConclusionsThe results suggest that POAF after cardiac surgery is associated with an increased occurrence of most short- and long-term cardiovascular adverse events. However, the causality of this association remains to be established. 相似文献
9.
10.